[ad_1]
The “Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering.
This pipeline guide provides an overview of the Nasopharyngitis pipeline landscape.
Companies Involved in Therapeutics Development
-
Adare Pharma Solutions
-
Charleston Laboratories Inc
-
Eurofarma Laboratorios SA
-
Firebrick Pharma Pty Ltd
-
Pfizer Inc
-
SaNOtize Research & Development Corp
-
SSP Co Ltd
-
Tris Pharma Inc
Drug Profiles
-
(Acetaminophen + Fexofenadine + Phenylephrine)
-
Guaifenesin ER
-
Hydrocodone bitartrate + Undisclosed drug
-
IMP-1088
-
NORS-1002
-
ORB-110
-
Povidone iodine
-
Small Molecule to Inhibit MAPK13 for Asthma and Cold
-
ST-HT
-
TRN-123
-
TRN-124
-
TRN-125
Report Highlights
This pipeline guide Nasopharyngitis (Common Cold) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Nasopharyngitis (Common Cold) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasopharyngitis (Common Cold) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase …
Full story available on Benzinga.com
[ad_2]
Source link
